RE: Keep the faith20 Jan 2026 12:30
Fact‑Checked Response to Roger
Roger, several of your claims are factually incorrect, so let’s anchor this in what’s actually documented.
1. “You only have Tim’s word that P140 is groundbreaking.”
Not true.
Independent scientific bodies have validated P140:
• The Jackson Laboratory (US) independently confirmed P140’s mechanism of action, non‑immunosuppressive profile, and therapeutic effect.
• The March 2025 RNS reports direct evidence supporting P140’s unique mechanism — the first time this has been demonstrated.
• The January 2025 RNS outlines new discoveries enabling earlier diagnosis and better patient‑response prediction.
These are scientific findings, not CEO commentary.
2. “Jacksons didn’t verify Tim’s interviews.”
Correct — because their job is to verify science, not PR.
And the science is verified
3. “100‑bagger talk is scary.”
No credible poster is claiming instant 100‑bagger territory.
But a non‑immunosuppressive autoimmune therapy sits in a market worth tens of billions.
That’s not hype — that’s the autoimmune drug landscape.
4. “If £7 was even 1-in-10 likely, the herd would react.”
This misunderstands biotech.
Markets don’t price in scientific breakthroughs until:
• a partner signs
• Phase 3 is funded
• a pharma validates the commercial route
IMM is pre‑partnering.
Silence before a catalyst is normal.
5. “The CEO has never delivered anything.”
Factually wrong.
Under Tim McCarthy, IMM has delivered:
• independent validation of P140’s mechanism
• major autoimmune‑science breakthroughs (2025)
• strengthened IP
• active global partnering discussions
• a validated non‑immunosuppressive therapy platform
Timelines can be debated — but “never delivered anything” is false.
Summary
Roger’s post relies on:
• incorrect assumptions
• misunderstanding of biotech valuation
• ignoring documented scientific evidence
• misrepresenting the CEO’s track record
The facts show:
• P140’s mechanism of action has been independently validated
• IMM’s 2025 RNS releases confirm major scientific breakthroughs
• The CEO has delivered substantial scientific and IP progress
• Market reaction does not precede partnering — it follows it
If we’re going to debate IMM, let’s at least start from a factual foundation.
Sign In
Follow the stocks
